| Literature DB >> 19268405 |
Valentina Zuliani1, Caterina Carmi, Mirko Rivara, Marco Fantini, Alessio Lodola, Federica Vacondio, Fabrizio Bordi, Pier Vincenzo Plazzi, Andrea Cavazzoni, Maricla Galetti, Roberta R Alfieri, Pier Giorgio Petronini, Marco Mor.
Abstract
Benzylidene hydantoins have been recently reported as a new class of EGFR inhibitors. We describe here a simple and efficient methodology for the parallel solution-phase synthesis of a library of 5-benzylidene hydantoins, which were evaluated for antiproliferative activity on the human lung adenocarcinoma A549 cell line. Various substituents at positions 1, 3 and 5 on the hydantoin nucleus were examined. In the presence of a 5-benzylidene group and of a lipophilic substituent at position 1, most of the tested compounds inhibited cell proliferation at a concentration of 20 microM. Compound 7 (UPR1024), bearing 1-phenethyl and (E)-5-p-OH-benzylidene substituents, was found to be the most active derivative of the series. It inhibited EGFR autophosphorylation and induced DNA damage in A549 cells. Compound 7 and other synthesized 5-benzylidene hydantoin derivatives increased p53 levels, suggesting that the dual mechanism of action was a common feature shared by compound 7 and other member of the series.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19268405 DOI: 10.1016/j.ejmech.2009.01.035
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514